GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (OTCPK:AAVXF) » Definitions » Ending Cash Position

Abivax (Abivax) Ending Cash Position : $274.75 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Abivax Ending Cash Position?

Abivax's Ending Cash Position for the quarter that ended in Dec. 2023 was $274.75 Mil.

Abivax's quarterly Ending Cash Position increased from Dec. 2022 ($28.55 Mil) to Jun. 2023 ($28.82 Mil) and increased from Jun. 2023 ($28.82 Mil) to Dec. 2023 ($274.75 Mil).

Abivax's annual Ending Cash Position declined from Dec. 2021 ($68.59 Mil) to Dec. 2022 ($28.55 Mil) but then increased from Dec. 2022 ($28.55 Mil) to Dec. 2023 ($274.75 Mil).

Abivax Ending Cash Position Historical Data

The historical data trend for Abivax's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Ending Cash Position Chart

Abivax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.86 35.65 68.59 28.55 274.75

Abivax Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.59 120.91 28.55 28.82 274.75

Abivax Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Abivax's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=29.388+245.358
=274.75

Abivax's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=-13.327+288.073
=274.75

Abivax Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Abivax's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax (Abivax) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (OTCPK:AAVXF) » Definitions » Ending Cash Position
Comparable Companies
XPAR:VLA XPAR:NANO XPAR:DBV XPAR:IPH XPAR:IVA XPAR:AELIS XPAR:MEDCL XPAR:GNFT XPAR:TNG XPAR:ALSEN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ABVX:USA ABVX:France 2X10:Germany
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Website
https://www.abivax.com
Abivax SA is a France-based biotechnology company. It is focused on using antiviral technology platforms targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein in the nucleus or the cytoplasm of the infected cell during viral infection, the Immune stimulation platform focuses on invariant natural killer agonists and the Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma.